Twenty Years On: RECIST as a Biomarker of Response in Solid Tumours an EORTC Imaging Group - ESOI Joint Paper.
RECIST
biomarker
imaging
response
tumour
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
23
10
2021
accepted:
30
11
2021
entrez:
27
1
2022
pubmed:
28
1
2022
medline:
28
1
2022
Statut:
epublish
Résumé
Response evaluation criteria in solid tumours (RECIST) v1.1 are currently the reference standard for evaluating efficacy of therapies in patients with solid tumours who are included in clinical trials, and they are widely used and accepted by regulatory agencies. This expert statement discusses the principles underlying RECIST, as well as their reproducibility and limitations. While the RECIST framework may not be perfect, the scientific bases for the anticancer drugs that have been approved using a RECIST-based surrogate endpoint remain valid. Importantly, changes in measurement have to meet thresholds defined by RECIST for response classification within thus partly circumventing the problems of measurement variability. The RECIST framework also applies to clinical patients in individual settings even though the relationship between tumour size changes and outcome from cohort studies is not necessarily translatable to individual cases. As reproducibility of RECIST measurements is impacted by reader experience, choice of target lesions and detection/interpretation of new lesions, it can result in patients changing response categories when measurements are near threshold values or if new lesions are missed or incorrectly interpreted. There are several situations where RECIST will fail to evaluate treatment-induced changes correctly; knowledge and understanding of these is crucial for correct interpretation. Also, some patterns of response/progression cannot be correctly documented by RECIST, particularly in relation to organ-site (e.g. bone without associated soft-tissue lesion) and treatment type (e.g. focal therapies). These require specialist reader experience and communication with oncologists to determine the actual impact of the therapy and best evaluation strategy. In such situations, alternative imaging markers for tumour response may be used but the sources of variability of individual imaging techniques need to be known and accounted for. Communication between imaging experts and oncologists regarding the level of confidence in a biomarker is essential for the correct interpretation of a biomarker and its application to clinical decision-making. Though measurement automation is desirable and potentially reduces the variability of results, associated technical difficulties must be overcome, and human adjudications may be required.
Identifiants
pubmed: 35083155
doi: 10.3389/fonc.2021.800547
pmc: PMC8784734
doi:
Types de publication
Systematic Review
Langues
eng
Pagination
800547Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
Copyright © 2022 Fournier, de Geus-Oei, Regge, Oprea-Lager, D’Anastasi, Bidaut, Bäuerle, Lopci, Cappello, Lecouvet, Mayerhoefer, Kunz, Verhoeff, Caruso, Smits, Hoffmann, Gourtsoyianni, Beets-Tan, Neri, deSouza, Deroose and Caramella.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Eur Urol. 2017 Jan;71(1):81-92
pubmed: 27317091
J Natl Cancer Inst. 1999 Mar 17;91(6):523-8
pubmed: 10088622
Cancer Imaging. 2016 Mar 16;16:5
pubmed: 26984681
EJNMMI Res. 2021 Feb 12;11(1):15
pubmed: 33580383
Oncologist. 2017 Jan;22(1):61-69
pubmed: 28126915
Eur J Nucl Med Mol Imaging. 2015 Mar;42(3):370-6
pubmed: 25351506
J Magn Reson Imaging. 2019 Jun;49(7):e101-e121
pubmed: 30451345
BMC Cancer. 2016 Aug 23;16(1):672
pubmed: 27553491
J Natl Cancer Inst. 2015 Aug 21;107(11):
pubmed: 26296640
Eur J Cancer. 2019 Jun;114:89-96
pubmed: 31078973
Ann Nucl Med. 2010 Apr;24(3):157-61
pubmed: 20204552
Eur Radiol. 2011 Nov;21(11):2417-24
pubmed: 21796499
Int J Cancer. 2012 May 15;130(10):2359-65
pubmed: 21780098
J Clin Oncol. 2011 Aug 10;29(23):3114-9
pubmed: 21730273
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
J Nucl Med. 2015 Jun;56(6):955-61
pubmed: 25883122
Eur J Nucl Med Mol Imaging. 2015 Dec;42(13):2072-82
pubmed: 26219870
Acta Radiol. 2001 Mar;42(2):198-206
pubmed: 11259949
AJR Am J Roentgenol. 2004 Dec;183(6):1619-28
pubmed: 15547201
Curr Med Res Opin. 2016;32(4):731-9
pubmed: 26743800
J Nucl Med. 2012 Jul;53(7):1041-7
pubmed: 22627001
Eur J Cancer. 1999 Dec;35(13):1773-82
pubmed: 10673991
J Magn Reson Imaging. 2015 Oct;42(4):908-19
pubmed: 25758543
Cancer. 1981 Jan 1;47(1):207-14
pubmed: 7459811
Eur J Cancer. 2020 Jan;124:25-36
pubmed: 31710995
Eur J Cancer. 2014 Jul;50(10):1847-1853
pubmed: 24726734
Anal Bioanal Chem. 2014 Oct;406(26):6499-512
pubmed: 24853859
Lung Cancer. 2005 Jul;49(1):95-108
pubmed: 15949595
AJR Am J Roentgenol. 2010 Aug;195(2):310-20
pubmed: 20651185
Front Oncol. 2020 May 07;10:572
pubmed: 32457831
Insights Imaging. 2020 Jul 16;11(1):83
pubmed: 32676924
Radiology. 2015 Dec;277(3):813-25
pubmed: 26267831
Diagnostics (Basel). 2016 Feb 01;6(1):
pubmed: 26838804
Eur Radiol. 2017 Nov;27(11):4552-4562
pubmed: 28396997
J Magn Reson Imaging. 2020 Dec 31;:
pubmed: 33382151
Virchows Arch. 2009 Oct;455(4):375-81
pubmed: 19760433
Pigment Cell Melanoma Res. 2016 Sep;29(5):572-7
pubmed: 27333363
Semin Nucl Med. 2020 Nov;50(6):488-504
pubmed: 33059819
Cancer Immunol Immunother. 2018 Dec;67(12):1825-1832
pubmed: 30171269
Acta Oncol. 2010 May;49(4):509-14
pubmed: 20397778
Am J Surg Pathol. 2019 Dec;43(12):1600-1610
pubmed: 31524642
Nat Rev Clin Oncol. 2020 Dec;17(12):757-770
pubmed: 32632268
Eur Radiol. 2009 Nov;19(11):2728-38
pubmed: 19547986
Cancer. 2020 Jan 1;126(1):86-97
pubmed: 31584722
Eur J Cancer. 2009 Jan;45(2):268-74
pubmed: 19101138
Clin Cancer Res. 2011 Oct 15;17(20):6592-9
pubmed: 21880789
J Clin Oncol. 2014 Sep 20;32(27):3059-68
pubmed: 25113753
Technol Cancer Res Treat. 2012 Jun;11(3):279-88
pubmed: 22417064
Radiology. 2020 Jul;296(1):44-55
pubmed: 32396045
Eur J Nucl Med Mol Imaging. 2017 Aug;44(Suppl 1):17-31
pubmed: 28623376
Br J Cancer. 2004 Jun 14;90(12):2326-31
pubmed: 15162152
Ann Nucl Med. 2007 Dec;21(10):607-13
pubmed: 18092139
Eur J Cancer. 2016 Jan;53:5-15
pubmed: 26687017
J Clin Oncol. 2007 May 1;25(13):1760-4
pubmed: 17470866
Eur J Cancer. 2018 Jan;88:38-47
pubmed: 29182990
Int J Hyperthermia. 2021;38(1):623-632
pubmed: 33882792
Acad Radiol. 2021 Aug;28(8):e235-e239
pubmed: 32616417
J Clin Oncol. 2019 May 1;37(13):1102-1110
pubmed: 30860949
Eur Radiol. 2016 Jul;26(7):1991-8
pubmed: 26385804
Radiology. 2013 Nov;269(2):451-9
pubmed: 23824993
J Nucl Med. 2019 May;60(5):608-614
pubmed: 30361381
J Clin Oncol. 2007 May 1;25(13):1753-9
pubmed: 17470865
J Clin Oncol. 2018 Jun 1;36(16):1631-1641
pubmed: 29504847
Eur J Cancer. 2009 Jan;45(2):248-60
pubmed: 19095437
Diagn Interv Imaging. 2014 Jul-Aug;95(7-8):689-703
pubmed: 24951349
Cancer Imaging. 2018 Dec 11;18(1):50
pubmed: 30537991
J Nucl Med. 2009 May;50 Suppl 1:122S-50S
pubmed: 19403881
Lancet Oncol. 2011 Jun;12(6):583-93
pubmed: 21474379
J Thorac Oncol. 2008 Apr;3(4):351-7
pubmed: 18379352
Eur J Radiol. 2013 Nov;82(11):1831-9
pubmed: 22717124
Transl Oncol. 2014 Feb 01;7(1):23-35
pubmed: 24772204
Eur J Radiol. 2015 Jan;84(1):158-162
pubmed: 25467224
J Clin Oncol. 2012 Apr 1;30(10):1030-3
pubmed: 22370321
Semin Liver Dis. 2010 Feb;30(1):52-60
pubmed: 20175033
Front Oncol. 2020 Oct 29;10:519164
pubmed: 33194582
PLoS One. 2015 Mar 27;10(3):e0122151
pubmed: 25816249
Ann Oncol. 2012 Apr;23(4):948-54
pubmed: 21832285
Eur J Nucl Med Mol Imaging. 2018 Jul;45(8):1289-1296
pubmed: 29478079
Eur J Radiol. 2016 Mar;85(3):524-33
pubmed: 26860663
Cancer. 1976 Jul;38(1):388-94
pubmed: 947531
Eur Urol. 2015 May;67(5):952-8
pubmed: 25577718
Acad Radiol. 2019 Apr;26(4):489-501
pubmed: 29934024
PLoS One. 2014 Apr 04;9(4):e92211
pubmed: 24704912
Eur Radiol. 2010 Aug;20(8):1868-77
pubmed: 20306084
J Magn Reson Imaging. 2014 Jul;40(1):90-8
pubmed: 24923476
Clin Cancer Res. 2009 Dec 1;15(23):7412-20
pubmed: 19934295
Nucl Med Biol. 2012 Jul;39(5):666-70
pubmed: 22381783
JAMA. 2001 Mar 21;285(11):1500-5
pubmed: 11255427
J Clin Oncol. 2019 Dec 20;37(36):3546-3555
pubmed: 31675272
Tomography. 2020 Jun;6(2):177-185
pubmed: 32548294
Prostate. 2005 Oct 1;65(2):178-87
pubmed: 15948151
J Nucl Med. 2019 May;60(5):600-607
pubmed: 30389824
Lancet Oncol. 2017 Mar;18(3):e143-e152
pubmed: 28271869
J Nucl Med. 2004 May;45(5):784-8
pubmed: 15136627
Radiology. 2019 Feb;290(2):349-356
pubmed: 30398433
Sci Adv. 2020 Dec 11;6(50):
pubmed: 33310847
Cancer Cell. 2018 Jul 9;34(1):148-162.e7
pubmed: 29990497
Clin Transl Oncol. 2015 Jan;17(1):11-23
pubmed: 25373531
J Nucl Med Technol. 2015 Sep;43(3):222-6
pubmed: 26271802
Eur J Nucl Med Mol Imaging. 2005 Mar;32(3):294-301
pubmed: 15791438
Lancet Oncol. 2015 Jun;16(6):e270-8
pubmed: 26065612
Cancer Res. 2021 May 1;81(9):2522-2533
pubmed: 33589516
Curr Radiopharm. 2016;9(3):244-257
pubmed: 27774910
Science. 2019 Dec 20;366(6472):1473-1480
pubmed: 31699882
J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
pubmed: 10655437
Eur J Radiol. 2020 Dec;133:109359
pubmed: 33129104
Diagn Interv Imaging. 2016 Mar;97(3):287-96
pubmed: 26857787
Eur J Nucl Med Mol Imaging. 2013 Oct;40(10):1507-15
pubmed: 23754762
Insights Imaging. 2021 Mar 18;12(1):36
pubmed: 33738548
J Clin Oncol. 2013 Oct 1;31(28):3600-4
pubmed: 23650428
Radiology. 2016 Aug;280(2):576-84
pubmed: 26909647
Cell. 2020 Oct 15;183(2):363-376.e13
pubmed: 33007267
Clin Cancer Res. 2007 Jun 15;13(12):3470-81
pubmed: 17575209
Eur Radiol. 2009 Jan;19(1):193-200
pubmed: 18677488
Diagn Interv Radiol. 2020 Mar;26(2):87-94
pubmed: 32071023
Radiology. 2020 Oct;297(1):87-96
pubmed: 32749204
EJNMMI Phys. 2017 Dec;4(1):17
pubmed: 28560574
Eur J Radiol. 2017 Oct;95:96-101
pubmed: 28987705
J Nucl Med. 2009 Nov;50(11):1760-9
pubmed: 19837757
Eur J Nucl Med Mol Imaging. 2018 Oct;45(11):1862-1872
pubmed: 29725716
J Clin Oncol. 2009 Jan 20;27(3):404-10
pubmed: 19047292
Am Surg. 2019 Jun 1;85(6):645-653
pubmed: 31267907
Eur J Cancer. 2009 Jan;45(2):300-10
pubmed: 19095439
Radiol Imaging Cancer. 2021 May;3(3):e210008
pubmed: 33988475
J Clin Oncol. 2012 Jul 20;30(21):2684-90
pubmed: 22689801
Ann Oncol. 2017 Jul 1;28(7):1436-1447
pubmed: 28379322
Radiol Med. 2017 Apr;122(4):294-302
pubmed: 28070841
Ann Nucl Med. 2019 Oct;33(10):766-775
pubmed: 31338731
J Immunother Cancer. 2020 Apr;8(1):
pubmed: 32303619
Eur J Nucl Med Mol Imaging. 2010 Jan;37(1):181-200
pubmed: 19915839
Invest Radiol. 2014 Aug;49(8):509-17
pubmed: 24651664
Eur J Nucl Med Mol Imaging. 2008 Dec;35(12):2320-33
pubmed: 18704407
J Magn Reson Imaging. 2019 Jun;49(6):1617-1628
pubmed: 30350329
Ann Transl Med. 2019 Dec;7(Suppl 8):S379
pubmed: 32016097
J Nucl Med. 2012 May;53(5):701-8
pubmed: 22496583
Radiology. 2017 Jul;284(1):88-99
pubmed: 28301311
Clin Chim Acta. 2011 Nov 20;412(23-24):2085-8
pubmed: 21861994
Lancet Oncol. 2019 May;20(5):728-740
pubmed: 30952559
Histopathology. 2005 Aug;47(2):141-6
pubmed: 16045774
Acta Radiol. 2011 Jun 1;52(5):557-61
pubmed: 21498309
BMJ. 2017 Oct 4;359:j4530
pubmed: 28978555